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For the past three decades, most attention in heavy metal toxicology has been paid to cadmium,
mercury, lead, chromium, nickel, vanadium, and tin because these metals widely polluted the
environment. However, with the development of new materials in the last decade, the need for
toxicological studies on those new materials has been increasing. A group of rare earths (RE) is a
good example. Although some RE have been used for superconductors, plastic magnets, and
ceramics, few toxicological data are available compared to other heavy metals described above.
Because chemical properties of RE are very similar, it is plausible that their binding affinities to
biomolecules, metabolism, and toxicity in the living system are also very similar. In this report, we
present an overview of the metabolism and health hazards of RE and related compounds, including
our recent studies. Environ Health Perspect 104(Suppl 11:85-95 (1996)
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Occurrence and Industrial
Use of Rare Earths
A group of 15 transition metals in group III
ofthe periodic table are called lanthanoids
or rare earths (RE). They are lanthanum
(La) and 14 lanthanides. The lanthanides
consist of 14 elements: cerium (Ce),
praseodymium (Pr), neodymium (Nd),
promethium (Pm), samarium (Sm),
europium (Eu), gadolinium (Gd), terbium
(Tb), dysprosium (Dy), holmium (Ho),
erbium (Er), thulium (Tm), ytterbium
(Yb), and lutetium (Lu). In this report,
however, scandium (Sc) and yttrium (Y) are
included in the group ofRE because chem-
ical and toxicological characteristics ofthese
two transition metals in group III appear to
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be very similar to those ofRE. The Clarke
numbers (the ratio ofthe amount ofa par-
ticular element mainly in the earth's crust)
ofRE are shown in Table 1.
Although RE are not abundant in the
earth's crust, Ce, the most plentiful ele-
ment of RE, is about 100 times more
abundant than cadmium (Cd), one of the
most well-known heavy metals in toxicol-
ogy. The Clarke number of Ce is almost
the same as those ofcobalt, tin, zinc, and
vanadium. Unlike all other RE, Pm, found
as a decay product ofuranium in 1947, has
not been detected in the earth's crust (3).
The global annual demand of RE is esti-
mated to be about 30,000 tons (4,5).
China has the world's largest reserve,
which is sufficient to meet the global needs
ofRE for 1000 years (4,5).
Chemical Properties
of Rare Earths
The chemical properties of RE and the
detection limits of RE in atomic absorp-
tion, atomic emission, and mass spectrom-
etry are summarized in Table 1 (1,2).
Although +2, +4, and +5 valences are pos-
sible for some ofthe RE, their valences are
usually +3 when they are dissolved. One of
the most prominent features oflanthanoids
is what is called lanthanoid contraction
(6). From La to Lu, the radius of lan-
thanoid ions (+3) decreases as the atomic
number increases. This phenomenon is
due to attraction ofelectrons of4forbitals
by increasing positive charge ofthe nucleus
with the atomic number. Because the
radius of Ca2+ (0.99 A) is very close to
those of lanthanoids, lanthanoids have
been used for Ca2+ probes in biochemical
and physiological studies. The nitrates,
chlorides, and sulfates of RE are soluble
and their carbonates, phosphates, and
hydroxides are insoluble (6). The differ-
ences in solubility among these ionic forms
ofRE seem to determine the metabolic fate
of RE in the biological system. In general,
the toxicity oflanthanoids decreases as the
atomic number increases, probably due to
greater solubility and ionic stability of
heavier lanthanoids (7).
It is known that RE and organic ligands
produce metal-ion complexes. The stability
constants of RE3+-citrate, RE3+-nitrilotri-
acetic acid (NTA), RE3+-ethylenediamine-
N,N,N',N'-tetraacetic acid (EDTA), and
RE3+-diethylenetriaminepentaacetic acid
(DTPA) are 6.5 to 8.5, 10 to 13, 16 to 23,
and 20 to 23, respectively (8,9). These
chelated RE have been used in toxicological
studies (vide infra).
Exposure to Rare Earths
It was not until the nuclear era that atten-
tion was addressed to the health effects of
RE. A fission product, 144Ce, was found in
animal bones and clams (10) and in the
lungs and lymph nodes obtained from
deceased persons who had inhaled nuclear
explosion aerosols (11).
Besides irradiation effects ofradioactive
nuclides, inhaled RE probably cause granu-
lomatous lesions in the lung or pneumoco-
niosis (7). The concentration ofLa found
in smelter's lungs was 2 to 16 times higher
than in normal lungs (12); La, Ce, Nd,
Sm, Eu, Tb, Yb, and Lu were found in a
deceased photoengraver's lungs (13).
These workers are at risk ofpneumoconio-
sis; one worker, who had been exposed for
only 18 months to dust containing 60% of
RE (mainly Ce, La, and Nd), was reported
to have radiologic evidence ofpneumoco-
niosis (14). Industrial uses ofRE are shown
in Table 2. They have been used for ceram-
ics, fluorescent materials, abrasives, mag-
nets, etc. (15). To our knowledge, however,
RE concentration in the air ofwork places
has not been reported. There is no evidence
ofpneumoconiosis or chronic pulmonary
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Table 1. Chemical properties of rare earths.
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Table 2. Industrial uses of rare earths.
Element Industrial use
Sc Cathode-raytubes, lasers, fluorescent
materials
Y Superconductors, lasers, fluorescente
materials, catalysts, ceramics
La Superconductors, lighters, catalysts,
glass additives, ceramics, batteries
Ce Lighters, catalysts, glassadditives,
ceramics, magnets, abrasives
Pr Magnets, lighters, glass additives
Nd Magnets, lighters, lasers, glassadditives,
magneto-optical materials
Pm (-)
Sm Lighters, magnets, condensers, nuclear
reactorcontrol rods
Eu Fluorescent materials, imaging plates,
nuclear reactor control rods
Gd Magnets, glass additives
Tb Fluorescent materials, magneto-optical
materials
Dy Magnets, magneto-optical materials
Ho Electric materials
Er Glass additives
Tm Fluorescent materials, lasers
Yb Condensers
Lu Superconductors
Data from Ito (4) and Ohmachi (5).
reactions in laboratory animals, even
though YC13 and LaCd3 or oxides ofY, Nd,
and Ce have been proven to cause bron-
chitis, pneumonitis, and granulomatous
lesions (16-18).
Some radioactive RE nuclides have been
used for cancer (19,20) and synovitis ther-
apy (21,22). 90Y is a useful nuclide for clin-
ical use because it has a moderate half-life
(64 hr) and it is a pure n-emitter with high
energy (2.28 MeV) (23). In addition, 90Y is
easily separated by column chromatography
from 90Sr, which has a very long half-life
(28.8 years). It has been shown that Tm3+,
Tb3+, and Yb3+ have a high affinity for
tumor cells (24-27). It is interesting to
note that Tb3+ was temperature-depen-
dently taken up by tumor cells (MCF-7),
and cisplatin, a well-known anticancer
drug, reduced the binding ofTb3+ to those
tumor cells (25). However, there is a con-
tradictory report that has shown that La
concentration in malignant laryngeal tissue
was lower than in nonmalignant adjacent
tissues, although serum La concentrations of
laryngeal cancer patients were significantly
higher than those ofnormal subjects (28).
Recently, DTPA-chelated Gd (gadopen-
tetate dimeglumine), tetraazacyclodode-
canetetraacetic acid (DOTA)-chelated Gd
(gadoterate meglumine), and Gd-HP-
D03A (gadoteriol) have been used as
magnetic resonance imaging-contrast
reagents (29,30). Although clearance of
those intravenously (iv) injected imaging-
contrast reagents have been reported to be
rapid, it is possible that some ionic Gd is
released from the complexes. Ionic RE are
rapidly changed to colloidal RE (hydroxide
and phosphates) in blood, and the colloidal
RE are taken up by the reticuloendothelial
system in the liver (30). Gd was found in
the breast milk of a lactating patient who
received an iv injection of gadopentetate
dimeglumine (31).
It is also reported that Ce is a potent
antiseptic drug for Gram-negative bacteria
and fungi (32) and swabbing ofLa is effec-
tive in protecting teeth from caries (33,34).
Thus, toxicological studies ofRE are needed
not only from the standpoint ofenviron-
mental or industrial hygiene but also for
medical treatment.
InteractionofRareEarths
withCells orBiomolecules
Tb3+ binds to Ca2+ binding sites of the
intestinal brush-border membrane (35)
and surfaces ofplatelets (36) and vascular
smooth muscle (37). When bound to
membranes, the fluorescence ofTb3+ is
increased probably by energy transfer to
aromatic residues such as tyrosine (35).
Tb3+ and Pm3+ are removable from the
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surfaces ofplatelets and smooth musde by
both Ca2+ and La3+ (36,37). Lanthanoids
are also known to bind to Ca2+ or Mg2+
binding sites ofcalmodulin (38), ATPase
ofsarcoplasmic reticulum (39,40), cystatin
(41), and phosphatidylserine (42). The
binding mode to calmodulin, which has
two high-affinity and two low-affinity Ca2+
binding sites, has been shown to be differ-
ent among lanthanoids. Lu3+ and Er3+ bind
like Ca2 , Eu3+ and Tb3+ bind in the oppo-
site order from Ca2+, and La3+ and Nd3+
bind in a mode between them (38). La3+
has been shown to inhibit the Ca2+-depen-
dent release ofchemical mediators such as
catecholamine from the adrenal medulla
and histamine from mast cells (43).
It has been reported that Sc3+, Y3+, and
La3+ bind to globulin and DNA (44), and
transferrin is a major Sc3+- or Y3+-binding
protein in blood plasma (45,46). La3+ and
Nd3+ have anticoagulant action (47,48);
inhibition of prothrombin-thrombin
transformation or blood coagulant factors
such as VII, IX, and X may be responsible
for the anticoagulant effect ofthose ions.
Deposion, Retntion, Metabolism,
dClearanceofRare Earths
Inhalation or Intratracheal Instilation.
As shown in Figure 1, inhaled or intratra-
cheally instilled RE chlorides have been
shown to accumulate in alveolar and tissue
macrophages and alveolar walls (16,17,49,
50). In macrophages RE have been shown
to localize in lysosomes; it is proposed that
RE are changed to insoluble phosphates in
lysosomes according to Gomori (phos-
phatase) reaction (49). The transmission
electron microscopy and X-ray microanaly-
sis revealed intratracheally instilled Y and
La deposits in basement membranes of
pneumocytes (16,17).
Half-times ofY and La in the rat lung
have been reported to be 168 (16) and
244 days (17), respectively, when these RE
were instilled intratracheally as chlorides.
Rhoads and Sanders (51) have reported a
half-time ofintratracheally instilled Yb2O3
in the rat lung of21 days. In these intratra-
cheal instillation studies, translocation of
RE to extrapulmonary tissue was marginal
or below the detection limit. On the other
hand, it has been shown that significant
amounts ofinhaled CeCl3 (52), Ce(OH)3
(53), and Y (chemical form is unknown)
(54) were translocated to the skeleton and
liver in rats or hamsters. It has also been
reported that a half-time of inhaled
Ce(OH)3 was 140 days following initial
rapid clearance in the rat lung (53). The
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Figure 1.Transmission electron micrographs ofalveolar macrophages retrieved in bron-
choalveolar lavage fluid (A, x3,640) and lung tissue (B, x1,344; C, x1,848). Male
Wistar rats received intratracheal instillation ofYCI3ata dose of 100 pg Y/rat andwere
killed at 7 days postinstillation. Yttrium was detected in lysosomes of macrophages
(arrowheads) in both free (A) and granulomatous types (B), and in basement mem-
branes(arrows, C) byX-raymicroanalysis. Reproduced from Hirano etal. (16).
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differences in the extrapulmonary translo-
cation of RE between the intratracheal
instillion and inhalation studies may
be due to absorption ofRE from the upper
airways or gastrointestinal tract after
being transported through the esophagus.
Another factor that influences the pul-
monary retention and translocation of RE
is the dose of RE in the lung because it
has been shown that translocation of Y
from the lung to the bone decreased as the
deposition in the lung increased (54).
The half-time ofintratracheally instilled
RE chlorides in the lung is relatively long
(vide supra) compared to those ofother sol-
uble metal salts such as cadmium chloride
(14 days) (55) and cupric sulfate (7.5 hr)
(56). However, when rats were exposed to
aerosols of gadopentate dimeglumine, a
half-time of Gd in the lung was 2.16 hr
(57). These results suggest that gadopentate
dimeglumine was stable in the alveolar space
and was hardly taken up by macrophages
because oflimited release ofionic Gd from
the complex.
Intravenous Injection. Whole body
retention and tissue distribution of iv-
injected RE primarily depend on the stabil-
ity ofRE in blood. Urinary excretion ofCe
during 14 days was less than 1% of the
dose following injection ofCeCl3 in mice
(58), and a half-time of iv-injected CeCl3
was about 10 years in beagle dogs (59). On
the other hand, chelated RE seems to be
excreted rapidly; a whole body half-time of
Tm3+-citrate was about 2.5 hr in rats (24),
and approximately 50% of iv-injected
Sm3+-ethylenediaminetetramethylene
phosphonic acid (EDTMP) was excreted
in 8 hr in humans (60). Intravenously
injected DTPA-chelated Gd was excreted
rapidly via urine after transient accumula-
tion in the kidney, and only 2% of the
injected dose remained in the body at 2 hr
postinjection; GdCl3 was taken up by retic-
uloendothelial cells, and 72% was accumu-
lated in the liver and spleen in rats (61-63).
It has also been shown that EDTA-chelated
Sc was rapidly taken up by the kidney with
subsequent elimination via the urine, while
ScCl3 was extensively deposited in the liver
and spleen in mice (64). We have reported
that iv-injected YCl3 was taken up by
phagocytes of the liver and spleen in rats
and the half-time ofY in the liver was 144
days (46). Taken together, chelated RE are
excreted mainly via urine after transient
accumulation in the kidney and their whole
body half-times are several hours; RE chlo-
rides are taken up by the liver and spleen,
and those RE are not easily excreted.
The whole body retention ofiv-injected
chelated RE fits to a three-phase model
shown by the following equation:
% Retention = Ae-(O.693/Ta)t
+ Be-(0.693/Tb)t
+ Ce-(0.693/Tc)t [1]
where A, B, and C are constants
(A+B+C=100), and Ta, Tb, and Tc
denote half-times offast, intermediate, and
slow phases, respectively. Table 3 shows
half-times of iv-injected RE in the three-
phase model (64-67). Hiraki et al. (66)
suggested that the fast, intermediate, and
slow phases represent excretion via urine,
from the soft tissues, and bone, respec-
tively. These results indicate that although
iv-injected chelated RE is excreted rapidly
via urine, RE deposited in the bone is
excreted very slowly.
It has been shown that accumulation of
Sc3+-citrate (low stability) in the liver,
spleen, and bone was much higher than
that ofSc3+-EDTA (high stability) follow-
ing iv injection in mice (68). Rosoffet al.
(68) also have shown that when Sc3+-NTA
(intermediate stability) was injected, a rela-
tively high concentration ofSc was accumu-
lated in the bone compared to Sc3+-citrate
or Sc3+-EDTA. Yb accumulated in rat off-
spring through milk following iv injection
ofYbCl3, Yb3+-EDTA, and Yb3+-DTPA
into rat mothers, and the transfer ofYb to
new-born babies increased in this order (69).
From a detoxication point ofview, it is
interesting to note that injection ofCa2+- or
Zn2+-DTPA has been proven to be effective
in removing Yb (70,71), Sc (72), and Ce
(73) from the body. Liposome-encapsu-
lated DTPA seems to be more effective
than DTPA itself (70,71). Injection of
either Na+2, Ca2+-EDTA or Na+3, Ca2+-
DTPA into Yb-exposed rat mothers has
been proven to be effective in reducing the
transfer ofYb to their offspring (69).
Rossoff et al. (68) have suggested that
RE chlorides are changed into colloidal
forms ofhydroxide, phosphate, and car-
bonate in blood. We have shown that Y
was distributed to a high molecular weight
fraction (colloidal material containing pro-
teins and some minerals such as calcium,
phosphorus, and iron), transferrin, and a
low molecular weight fraction (probably
citrate) in the blood plasma; the percent of
colloidal fraction of injected Y increased
with dose ofYCl3 as shown in Figure 2
(46). Uptake ofY by the liver and spleen
also increased with the dose ofYCl3 (46).
In Japanese quails, iv-injected LaCl3
and CeCl3 were deposited mainly in the
liver and oocytes (74,75), and vitellogenin
is a major lanthanoid-binding protein in
these birds (75). At a dose of 15 pmol
Gd/100 g body weight (bw), 80% of the
dose was deposited in the liver; at doses
below 0.15 pmol Gd/100 g bw, 80% of
the dose was deposited in the oocytes (75).
Deposition of iv-injected GdCI3 in the
liver, oocytes, and ova decreased as blood
vitelloginin concentration was increased by
intramuscular injection ofestradiol in male
Japanese quails (76).
Intraperitoneal Injection. It is
reported that intraperitoneally (ip) injected
CeCl3 or Ce3+-citrate was deposited mainly
in the liver and skeleton in hamsters (52)
and rats (77). Electron microprobe and
ionic microanalysis revealed that ip-
injected CeCI3 was localized in lysosomes
ofhepatocytes and Kupffer cells, in lyso-
somes of bone marrow macrophages, and
basement membranes of proximal convo-
luted tubules in the kidney of rats (50).
Although Tb content in the liver was the
largest among organs tested, tissue concen-
trations ofTb (1.g Tb/g tissue) were higher
in the seminal vesicles, pancreas, and
spleen than in the liver ofmice (78).
Following ip injection ofLu3+-citrate in
mice, Lu was deposited in the skeleton,
liver, kidney, spleen, and lung, in this
order (79). However, the percent ofdepo-
sition in the liver was increased as the dose
of Lu3+-citrate increased, and the percent
ofdeposition in the skeleton was decreased
as the dose increased (79). As described
above, Ca2+ or Zn2+-DTPA has been
effective in removing RE deposited in the
tissues following ip injection (77,80,81).
Per OralAdministration. By oral
intake through drinking water or per oral
Table 3. Half-times of intravenously injected chelated rare earths for fast, intermediate, and slow phases in the
three-phase clearance model.
Chelated RE Animal Ta (fast) Tb(intermediate) Tc(slow) Reference
Sc-EDTA Mouse 12.75 min 40.2 min 5351 min (64)
Sc-citrate Rat 1.0 day 7.1 days 485 days (65)
Tm-citrate Rat 3.4 hr 99 hr 106 days (66)
Yb-citrate Rat 3.6 hr 194 hr 850 days (67)
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(po) administration, ionic RE was absorbed
mainly from the ileum (82-84) and
deposited in the skeleton, teeth, and soft
tissues such as the lung, liver, and kidney
(33,85-87). Although swabbing of teeth
with La(NO3)3 is known to replace Ca
with La in the enamel in rats (33) and
hamsters (88), La absorbed from the small
intestine has also been shown to deposit in
the teeth (33). It has been shown that
13.3% of po-administered CeCI3 was
excreted via bile during the first 4 hr in rats
(89), suggesting that a significant amount
of Ce was absorbed from the intestine.
However, the intestinal absorption of RE
seems to depend on the diet. Retention of
Pm in the soft tissues in neonatal rats was
two orders ofmagnitude higher than that
in adult rats (82), probably because the
neonates were on milk diet (84,90).
Fasting significantly increased the absorp-
tion of RE from the gastrointestinal tract
(90,91). This phenomenon is not hard to
understand; it has been demonstrated that
about 45% ofpo-administered CeCI3 was
present in the gastrointestinal content even
1 day after the administration in pigs (86).
The po administration ofZn2+-DTPA
reduced the whole body retention ofCe to
1/20 to 1/30 ofthat in the untreated group
by chelating Ce present in the gut and
intestinal content (83,92).
Exposure to RE via Other Routes.
Absorption of RE from the skin is known
to be negligible (93); however, when
the skin was stripped or wounded, RE
seem to be absorbed into the body to some
extent (93,94). Inaba and Yasumoto (93)
reported that 4% of applied CeCl3 was
absorbed from the stripped guinea pig's
skin while 89% ofCsCl and 79% ofCoCl2
were absorbed from the skin under the
same experimental conditions. It has been
shown that Ce3+ was deposited in the liver,
spleen, and bone following subcutaneous
(sc) injection of Ce3+-citrate (95,96).
Intramuscularly injected CeCI3 has been
reported to accumulate in the lysosomes of
the liver in rats and hamsters (97). Allard
et al. (98) reported that 6% ofintracister-
nally injected Gd3+-DOTA was found in
the brain at 0.5 hr postinjection, and 58%
ofthe brain Gd was located in the soluble
fraction, suggesting that even chelated Gd
with high stability is taken up by the brain
to some extent.
Because RE is known to deposit in the
skeleton, it is interesting to know what
cells in the bone marrow take up RE. Only
macrophages take up ip-injected CeCl3 in
the bone marrow ofrats (50); however, La
was found in nuclear pores ofmarrow cells
(especially erythroid cells) and the cell sap
of light stromal cells when the rat bone
marrow cells were exposed to La(NO3)3 in
vitrounder fixing conditions (99,100).
Toxicity
Mortality. As shown in Table 4, iv-, ip-,
and po-administered ionic or chelated
forms of RE are not highly toxic as far as
the median lethal dose (LD50) is concerned.
However, is it really possible to determine
LD50 values for iv-injected RE? It has been
shown that the percent mortality peaked at
20 to 40 mg Pr(NO3)3 /kg bw following iv
injection in both mice and rats of both
sexes; however, the lethality then decreased
0.m
... ...l... ..
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Figure 2. (A) Time-course and (B) dose-related changes
in elution profile of Y in blood plasma on a gel filtration
column (Asahipak GST-520). Blood samples were
obtained from male Wistar rats at 10 and 30 min and 1,
3, 7, and 20 hr post ivinjection ofYCI3 at a dose of 1 mg
Y/rat (A) or at 1 hr post iv injection of YCI3 at doses of
0.1, 0.2, 0.5, 1, and 2 mg Y/rat (B). The eluate was
directly introduced to an atomizer of an inductively cou-
pled argon plasma-atomic emission spectrophotometer.
The atomic-emission intensity of Y was continuously
monitored. Reproduced from Hirano etal. (46).
Table 4. LD50 of REfollowing intravenous, intraperitoneal, and per os administration.
LD50,
RE Route Animal kg bodyweight Reference
La(NO3)3 ip Mouse 150 mg La (34)
CeCI3 iv Rat 10 mg Ce (101)
Ce(NO3)3 po Mouse 1178 mg (102)
EuCI3 ip Mouse 550 mg Eu (103)
EuCI3 Po Mouse 5000 mg Eu (103)
DyCl3 ip Mouse 585 mg (104)
DyCI3 Po Mouse 7650 mg (104)
HoCI3 ip Mouse 560 mg DyCI3 (104)
HoCI3 po Mouse 7200 mg DyCI3 (104)
ErCI3 ip Mouse 535 mg DyCl3 (104)
ErCI3 Po Mouse 6200 mg DyCl3 (104)
ScCI3 iv Mouse 24 mg Sc (64)
ScC13 ip Mouse 440 mg Sc (64)
Sc-EDTA iv Mouse 108 mg Sc (64)
Sc-EDTA ip Mouse 702 mg Sc (64)
RE(NO3)3a po Mouse 1876 mg RE(N03)3 (102)
RE(N03)3 Po Rat 1832 mg RE(NO3)3 (102)
RE(NO3)3 Po Guinea pig 1397 mg RE(NO3)3 (102)
'Mixture of La, Ce, Nd, Pr, and Sm.
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as the dose increased. Even the lethality was
abolished at 80 to 100 mg Pr(NO3)3/kg bw
(105). In this bell-shaped dose-response
mortality curve, mortality did not exceed
50% in male mice. Although more exten-
sive study is required to answer the question
about why the dose-response curve ofthe
percent mortality is bell-shaped, the colloid
formation of ionic RE in blood at higher
doses of RE chlorides or nitrates might be
resposible for the unusual dose-response
curve in lethality. A marked increase in
death due to pneumonia was found in
mice when they were subacutely exposed
to 30 mg/m3 of Gd2O3 dust (6 hr/day,
5 days/week, and up to 120 days) (106).
Effects ofRare Earths on the Lung. As
we described earlier, chronic exposure to
RE dust probably causes pneumoconiosis in
humans (14). It has been shown that intra-
tracheal instillation ofYC13 caused granulo-
matous changes in the rat lung (16).
Inhalational exposure to high concentra-
tions of Gd2O3 (106) and intratracheal
instillation ofYCI3 (16), LaCl3 (17), and
GdCl3 (107) have been shown to cause
pneumonitis and acute inflammation in the
lung, e.g., infiltration of neutrophils and
leakage ofenzymes and proteins into the
alveolar space, in mice and rats. The acute
toxicity ofYC13 in the rat lung was between
those ofZnO and Cd compounds, judging
from dose-related changes in lactate dehy-
drogenase activity in the bronchoalveolar
lavage fluid (16).
Effeets ofRare Earths on the Liver.
Intravenously injected RE chlorides increase
vascular permeability for low molecular
weight substances (108) and cause necrosis
in the liver (109). Subcutaneous adminis-
tration of Ce(NO3)3 has also been found
to cause hepatic necrosis (96). Hepatic
endoplasmic reticulum (ER) has been
shown to be the primary target of iv-
injected CeCl3 in the rat liver, and dila-
tion, disorganization, and degranulation of
rough ER and proliferation of smooth ER
occurred following,the iv injection (110).
Pretreatment of rats with pregnenolone-
16a-carbonitrile, spironolactone, and phe-
nobarbital, which are known to proliferate
smooth ER, and estradiol, a putative stabi-
lizer of smooth ER, have been shown to
reduce hepatic damage caused by CeCI3 in
rats (101). It has also been demonstrated
that pretreatment with pregnenolone 16a-
carbonitrile or nefolopin increased the rela-
tive liver weight and significantly reduced
mortality caused by iv injection ofCeCl3 in
mice (58), suggesting that the liver is the
primary target organ ofiv-injected CeCl3.
It has been shown that iv injection of
CeCl3 caused fatty liver in female rats
(110,111) but not in male rats (111).
Intravenous injection of YCl3, TbCl3,
HoCl3 and YbCl3 caused focal necrosis
with Ca deposition in rats but CeCl3 did
not (111). We have shown that patchy Ca
deposition occurred in the focal necrotic
area ofthe rat liver following iv injection of
YCl3 (-50 jig Y/g liver) (46). However,
the reason that fatty liver was limited to
female rats that received CeCI3 remained
unknown. It seems that iv injection of
CeCl3 produces lipid droplets in the liver
ofmale mice (109).
There is a battery of reports about
hepatic biochemical changes following iv
injection of ionic RE; these reports are
summarized in Table 5. There are differ-
ences in changes of RNA polymerase II
activity among nitrates ofPr, Nd, Sm, Gd,
Dy, and Er (120). The first three RE
decreased RNA polymerase II activity
while the latter three RE increased the
activity; only Pr and Nd nitrates decreased
RNA polymerase I activity while the
other four did not change the RNA poly-
merase I activity. Otherwise, the biochemi-
cal changes are consistent among RE; those
biochemical changes are increase in triglyc-
eride in the liver (105,110,113,117) and
increases in leakage of hepatic enzymes
into blood (46,105,111-116). RE-induced
hepatic injury seems to reduce P450 con-
tent and P450-related enzyme activities in
rat (113) and mouse (109,119); however,
the decreases in P450 activities (coumarin
7-hydroxylase and 7-ethoxyresorufin
O-deethylase) at 3 to 4 days after iv injec-
tion of CeCI3 were preceded by increases
in these enzyme activities at 1 to 2 days
postinjection in DBA/2 mice (109,119).
Serum very low density lipoprotein (VLDL)
and high density lipoprotein (HDL) have
been shown to be decreased following iv
injection ofPr(NO3)3 in rats; the decrease
is probably due to a decrease in hepatic
secretion ofthese lipoproteins (118). It has
also been reported that ip injection of
CeCl3 causes lipid peroxidation and a
decease in glutathione reductase activity in
the chickliver (121).
Although serum glutamic-oxaloacetic
and glutamic-pyruvic transaminase acti-
vities, well-known markers for acute
hepatic injury, were increased with doses of
Table 5. Hepatic and liver-associated biochemical changes following intravenous injection of rare earth.
Effect RE compound Animal Dose Reference
s-GOT, s-GPT I CeCI3, Ce(NO3)3, La(NO3)3,YCI3 Rat 2-10 mg Ce/kg, 3-10 mg La/kg, 1 mg Y/rat (46,112,113)
Pr(NO3)3 Rat, mouse 3-40 mg Pr(NO3)3/kg (105,113-115)
s-SDH I Ce(NO3)3, Pr(NO3)3, La(NO3)3 Rat 3-10 mg RE/kg (113)
s-OCTT CeCI3, PrCI3, LaCI3 Rat 1.5-3 mg Ce/kg, 3 mg Pr/kg, 0.75 mg La/kg (111,116)
YCI3, TbCI3, HoCI3, YbCI3 9 mg Y/kg, 35 mg Tb/kg, 40 mg Ho/kg, 60 mg Yb/kg
s-FFA Pr(NO3)3 Rat 10 mg Pr(NO3)3/kg (117)
s-VLDL, s-HDL, s-triglyceride 4- Pr(NO3)3 Rat 10 mg Pr(N03)3/kg (118)
Triglyceride (liver) T CeCI3, Rat 10 mg CeCI3/kg (110)
Pr(NO3)3 Rat, mouse 7 mg Pr/kg, 10-20 mg Pr(NO3)3/kg (105,113,117)
ATP -1 CeCI3 Rat 10 mg CeCI3/kg (110)
P450, AH, AD 4- Pr(NO3)3 Rat 7 mg Pr/kg (113)
COH, EROD, Cyp2a-4/5-mRNA 1,T1 CeCI3 Mouse 2 mg CeCI3/kg, 0.5-2 mg Ce/kg (109,119)
RNA polymerase I Pr(NO3)3, Nd(NO3)3 Rat 35 pmol/kg (120)
RNA polymerase 11 T Gd(NO3)3, Dy(NO3)3, Er(NO3)3 Rat 35 pmol/kg (120)
RNA polymerase II -1 Pr(N03)3, Nd(NO3)3, Sm(NO3)3 Rat 35 pmol/kg (120)
LPO 1 LaCI3 Chick(ip) 250 mg LaCI3/kg (121)
GR I LaCI3 Chick(ip) 250 mg LaCI3/kg (121)
Abbreviations: s-GOT, serum glutamic-oxaloacetic transaminase; s-GPT, serum glutamic-pyruvic transaminase; s-FFA, serum free fatty acid; s-VLDL, serum very low density
lipoprotein; s-HDL, serum high density lipoprotein; ATP, adenosine 5'-triphosphate; AH, aniline hydroxylase; AD, aminophenazone demethylase; COH, coumarin 7-hydroxylase;
EROD, 7-ethoxyresorufin 0-deethylase; LPO, lipid peroxidation; GR, glutathione reductase.
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iv-injected Pr(NO3)3 up to 20 mg/kg bw,
their activities were remarkably decreased
at doses higher than 20 mg/kg bw in
rats (105). Because formation ofcolloidal
RE in blood significantly increased with
doses ofYCI3 (46), it is reasonable to sup-
pose that iv-injected RE was taken up by
Kupffer cells rather than by hepatocytes at
doses higher than a maximum lethality.
The uptake ofcolloidal RE by Kupffer cells
may have reduced the uptake of RE by
hepatocytes, resulting in the reduced
hepatic injury.
Effects ofRare Earths on the Kidney,
Spleen, and Gastrointestinal Tract.
When the rat kidney was perfused with
Krebs-Henseleit bicarbonate buffer con-
taining 3 to 5.5 mM of chelated Dy
(tripolyphosphate or triethylenetriamine-
hexaacetic acid) for 30 min, urinary con-
centrating ability was decreased and renal
vascular resistance was increased (122).
Ethoxyresorufin O-deethylase activity in
the kidney was decreased following iv
injection of CeCl3 in mice (109). Lipid
peroxidation was increased and glutathione
content and antioxidant enzymes were
decreased in the renal cortex following ip
injection ofLaCl3 in chicks (123).
Intravenous injection ofLaCd3 or CeCl3
increased vascular permeability ofthe spleen
in mice (108), and both sc and po adminis-
tration ofCe3+-citrate caused hypertrophy,
reticuloendothelial hyperplasia, and hyper-
active lymphoid follicles in mice (96).
Significant Ca deposition occurred in the
spleen following ip injection ofYCl3 (46).
Oral administration ofCe3+-citrate has been
shown to cause focal hemorrhage, necrosis
ofmucosa, and neutrophil infiltration in the
stomach and duodenum (96).
Effects ofRare Earths on the Eye and
Skin. Exposure to EuCl3, DyCl3, HoC13,
and ErCI3 caused conjunctivitis in rabbits
when these RE chlorides were applied
directly to their eyes (103,104). These RE
chlorides have also been demonstrated to
cause severe irritation when they are applied
to abraded skin in rabbits and cause epila-
tion and nodule formation when injected
intradermally in guinea pigs (103,104). It
has also been shown that sc injection ofRE
chlorides caused local calcification with
mild fibrosis and accumulation ofmultinu-
cleated giant cells, and the calcification area
was increased with dose (up to 2 mg ofRE
chlorides) in mice (124).
Effects ofRare Earths on the Blood,
Bone Marrow and Other Cells/Tissues.
Intraperitoneal injection ofLaC13 or NdCl3
significantly decreased the contents of
sulfhydryl groups, cholesterol, phospholipid
and lipid peroxides, and activities ofgal-
actosidase, glucuronidase, acetylcholinest-
erase, NADH dehydrogenase, ATPase, and
p-nitrophenyl phosphatase in the red blood
cell membrane in chicks. (125). It has also
been shown that ip injection of LaCl3
decreased contents ofsulfhydryl groups and
lipid peroxides and increased activities of
glutathione peroxidase, glutathione reduc-
tase, glutathione-S-transferase, and catalase
in the bone marrow ofchicks (126). Slight
but significant aberration ofbone marrow
cells has been found following po adminis-
tration of 1/10 ofLD50 dose ofRE nitrates
in mice (102); however, no aberration was
observed in spermatogoriia, spermatocytes,
and sperm in those mice.
Basu et al. (127) have shown that the
ip injection of LaCl3 caused a marked
depression in the activities ofneural Ca2+-
ATPase, Mg2+-ATPase, and cholinesterase
in chicks. The depression ofthese enzyme
activities may be related to inhibitory
effects ofLa3+ on binding ofCa2+ to brain
synaptosomal membrane.
The median lethal concentration (LC50)
for rat alveolar macrophages of CdO,
CdCl2, LaC13, CeCl3, and Nd2O3 were 15,
28, 52, 29, and 101 pM, respectively, in
vitro, and although La2O3 and Ce2O3 were
less toxic than LaCl3 and CeCl3, respec-
tively, Nd2O3 was more toxic than NdCl3
(128). Cytotoxicity ofsuperconducting par-
tides (YBa2Cu3067) has been shown to be
almost the same as that ofquartz (DQ12)
using bovine alveolar macrophages (129).
These in vitro studies using macrophages
have been carried out in culture medium
without serum. Thus, it remains unan-
swered as to how addition ofserum (fetal
bovine serum) in the macrophage culture
system affected the cytotoxicity ofRE.
Effects ofRare Earths on Behavior,
Pregnaney, and Offspring. Ce-exposed
mice exhibited significantly reduced open
field behavior; ambulations were depressed
after 10 sc injections (at 3-day intervals) of
Ce3+-citrate at 20 mg Ce/kg body weight
(95), and ambulation and rearing were
depressed following sc injection of Ce3+-
citrate at doses of 136 to 173 mg Ce/kg
bodyweight (96).
A single sc injection ofCe3+-citrate at
a dose of 80 mg Ce/kg bw during either
pregnancy or the lactating period signi-
ficantly reduced the body weight of off-
spring in mice (130). It has also been
shown that ip injection of LaCl3 (44 mg
La/kg bw) increased the cessation ofpreg-
nancy and decreased the average litter size
in pregnant mice (131). No malformation
was observed in fetuses, even when the
dams were administered po with a high
dose ofRE(NO3)3 (331 mg/ RE(NO3)3/kg
bw) starting from the 16th day ofgestation
in rats (102).
Effects ofRare Earths on Growth,
Longevity, and Carcinogenicity. The aor-
tic contents ofcholesterol, collagen, elastin,
and Ca and urinary hydroxyproline excre-
tion were increased in rabbits when they
were kept on an atherogenic diet; intake of
La (40 mg LaCl3/kg bw/day) significantly
reduced the increases of these atheroscle-
rotic parameters (132). The growth of
mice was depressed when they were given 5
ppm ofSc3+ or Y3+ in drinking water, and
the longevity was increased in Y3+-fed mice
(133). However, no effect on growth was
found in rats that had been fed a diet con-
taining 0.1 to 1% of DyCl3, HoCl3, or
ErCl3 for 12 weeks (104).
No carcinogenicity of RE has been
found in animals (102,113,133). In addi-
tion, at 0.5 to 50 mg/ml of RE(NO3)3 (a
mixture ofCe, La, Nd, Pr, and Sm), Ames
mutagenicity tests were negative (133).
Rare Earths as Ca" Antagonists. The
tonus and contractility ofthe rabbit ileum
in response to acetylcholine or nicotine was
decreased dose dependently by EuCl3
(103), DyCl3, HoCl3, and ErCI3 (104) in
vitro. In the guinea pig, Tm3+, La3+, and
Ce3+ inhibited contractile responses to K+
of longitudinal ileal muscle and the
inhibitory effects increased in this order
(134). The inhibitory effects of La3+ and
Tm3+ on K+- or noradrenaline-induced
contractile responses have also been
demonstrated using the vas deferens ofrats
(135). The inhibitory effects of RE3+ on
the contractility are due to displacement of
membrane-bound Ca2+ with RE3+ (134)
or modulation of the membrane stability
by RE3+ (135).
Enzymatic Functions ofRare Earths.
Very recently it was found that RE ions
hydrolyze RNA dinucleoside monophos-
phates (136) and phosphatidylinositol
(137) in vitro under physiological condi-
tions (pH 7.5 - 8.5, 30°C). Hydrolysis of
phosphatidylinositol seems to be specific to
RE because Fe3+, Zn2+, and Cu2+ were
found completely inactive (137). It has also
been shown that RE ions catalyze cAMP
production from ATP-like adenylate
cyclase (138), and Ce4+ hydrolyzes cAMP
(139) under physiological conditions.
Although it is not clear whether those in
vitro catalytic functions of RE ions are
related to toxic effects ofRE in vivo, those
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findings may shed light on the mechanism
oftoxicity ofRE.
Summary and Implications
The chemical forms ofRE compounds pri-
marily determine deposition and retention
of RE following iv, po, sc, intratracheal,
and inhalational exposure. The clearance of
chelated RE from the body depends on the
stability ofthe complexes. The chelated RE
are excreted rapidly via urine, while unche-
lated ionic RE easily form colloid in blood,
and the colloidal material is taken up by
phagocytic cells ofthe liver and spleen.
Although the bone is one ofthe target
organs ofRE, it is not clear what cells in the
bone take up the most RE- macrophages,
erythroid cells, or light reticular cells. It is
important to investigate effects of RE on
bone marrow cells because the clearance of
RE from the bone is known to beveryslow.
Inhalational or intratracheal exposure
ofanimals to RE has been proven to cause
acute pneumonitis with neutrophil infiltra-
tion in the lung; long-term exposure to RE
dust seems to cause pneumoconiosis in
human. However, the mechanism of neu-
trophil recruitment or interaction of RE
with lung cells has not been fully investi-
gated, except that intratracheally injected
YC13 and LaCl3 were deposited in the
lysosomes ofmacrophages and basement
membranes ofpneumocytes.
Mortality studies reveal that RE are not
highly toxic (LD50 values for iv-injected
RE are 10 to 100 mg/kg/bw and those
of ip-injected RE are 150 to 700 mg/kg
bw); cytotoxicity of RE to macrophages is
comparable to that ofCd or silica in vitro.
These discrepancies in lethal toxicity
between in vivoand in vitrostudies seem to
be due to chemical forms of RE in the
experimental system because those cytotox-
icity studies were carried out in culture
medium without serum. It is ofinterest to
study the toxicity ofRE using macrophages
and othercells invarious culture conditions.
There is much evidence that lanthanoid
ions function as Ca2+ antagonists in vitro;
however, there are few in vivo studies that
relate the toxicity of RE to Ca2+-displace-
ment from cells or biomolecules.
Because RE have been used directly in
humans for therapy ofcancer and synovitis
and for diagnosis by magnetic resonance
imaging, more extensive studies, including
chronic exposure experiments, are required.
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